Disclosed is a family of corroles for their use in the treatment of an infection by poxvirus.

The present disclosure relates to CDR defined antibodies targeting the 5T4 oncofoetal antigen (TPBG, 5T4, Wnt Activated Inhibitory Factor 1, WAIF1) which exhibit a binding affinity for human 5T4 antigen which is in the same order of magnitude as their affinity for cynomolgus monkey 5T4. Antibody-drug conjugates (ADCs), and their use in the treatment of human solid tumours and haematological malignancies are claimed.

Herein is reported a bispecific antibody comprising a first binding specificity that specifically binds to a haptenylated payload and a second binding specificity that specifically binds to a blood brain barrier receptor.

The present disclosure relates to novel chlorin-vitamin conjugates and method of making and using the chlorin-vitamin conjugates.

A rhodium-loaded porphyrin complex, comprising the porphyrin (meso-tri(4-sulfonatophenyl) mono(4-carboxyphenyl)porphine (C1S3TPP)) with coordinated with rhodium, effectively neutralizes the biological activity of naturally-occurring and synthetic opioids.

A method of targeting cancer tissue in a subject includes administering to the subject a plurality of functionalized Tymovirus virus or virus-like particles loaded with or conjugated to an imaging agent, a therapeutic agent or a targeting agent.

A method of treating or mitigating metastatic cancer in a subject having a primary tumor, by providing a prodrug system, the prodrug system comprising (1) a prodrug comprising at least one functional moiety and at least one linker linked to the at least one functional moiety, wherein the at least one functional moiety is inactive when linked to the linker, and wherein the at least one linker is cleavable by singlet oxygen, and (2) a sensitizer which when exposed to an activator results in generation of singlet oxygen by the sensitizer, causing cleavage of the at least one linker thereby activating the at least one functional moiety, wherein the sensitizer optionally is linked to the functional moiety via the at least one linker, administering the prodrug system to the subject, and exposing the primary tumor to the activator causing activation of the functional moiety and death of at least a portion of the primary tumor. Also disclosed is a method of making a whole-cell cancer vaccine, and using the vaccine to treat or mitigate metastatic cancer in a subject.

The present disclosure relates to novel chlorin-vitamin conjugates and method of making and using the chlorin-vitamin conjugates.

The invention relates to polynucleotide agents targeting a Patatin-Like Phospholipase Domain Containing 3 (PNPLA3) gene, and methods of using such polynucleotide agents to inhibit expression of a PNPLA3 gene and methods of treating subjects having Nonalcoholic Fatty Liver Disease (NAFLD) and/or a PNPLA3-associated disorder.

The present disclosure provides layer-by-layer compositions comprising a plurality of polymer bilayers. Each bilayer comprises a poly(N-vinylpyrrolidone) hydrogen-bonded a polyphenol (tannic acid) layer. In the compositions, at least one poly(N-vinylpyrrolidone) has conjugated thereon a plurality of manganoporphyrin moieties. The layer-by-layer compositions can be deposited on the cell aggregate surface or deposited on an underlying surface such as that of a silica core which, when removed creates a capsule having a hollow space for the addition of such as a therapeutic agent.